Citigroup
NVLN

Citigroup’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Citigroup’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,100
Closed -$3K – 7949
2018
Q3 		$3K Sell
1,100
-32,620
-97% -$115K ﹤0.01% 7584
2018
Q2 		$124K Buy
33,720
+30,549
+963% +$123K ﹤0.01% 5519
2018
Q1 		$11K Buy
3,171
+934
+42% +$3.96K ﹤0.01% 7035
2017
Q4 		$7K Buy
2,237
+2,234
+74,467% +$10.7K ﹤0.01% 7166
2017
Q3 		$0 Sell
3
-4,908
-100% -$39.3K ﹤0.01% 7581
2017
Q2 		$45K Buy
4,911
+16
+0.3% +$154 ﹤0.01% 5868
2017
Q1 		$52K Sell
4,895
-2,120
-30% -$21.7K ﹤0.01% 5675
2016
Q4 		$59K Buy
+7,015
New +$62.1K ﹤0.01% 6071

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $38.5M AUM 24.72% 1-Year Est. Return
BC
Broadfin Capital New York $403M AUM 100.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $1.58B AUM 31.19% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
DMK
David M. Knott $264M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return